National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium - PubMed
3 hours ago
- #Nirsevimab Impact
- #RSV Prevention
- #Pediatric Hospitalizations
- Nirsevimab introduction in Belgium for infants under 6 months during winter 2024-2025.
- National survey data from two systems covering 47% of pediatric beds shows reduction in RSV hospitalizations.
- 39% decrease in pediatric RSV-related hospitalizations and 57% decrease in intensive care admissions in 2024-2025 compared to previous season.
- Reductions mainly in infants under 6 months, with no changes in older children.
- Healthcare resource savings observed: shorter stays, less non-invasive ventilation, and reduced nutritional support.
- Study highlights need to increase uptake of preventive tools for better effectiveness.
- Emphasizes importance of national network for monitoring prevention efficacy over time.